- In the first- or second-line setting of advanced gastric cancer, the combination of lenvatinib plus pembrolizumab achieved a higher response rate than either drug alone had shown in previous studies.
Why this matters
- Many advanced gastric cancers are resistant or unresponsive to anti-programmed cell death protein 1 (anti-PD-1) drugs, underscoring the need for combination therapies.
- Open-label, single group, phase 2 trial in Japan (n=29).
- Funding: MSD.
- 26 of 29 patients had an Eastern Cooperative Oncology Group performance status of 0.
- 48% received treatment as first-line therapy, 52% as second-line therapy.
- Median follow-up, 12.6 months.
- Median PFS, 7.1 months.
- 20 of 29 (69%) patients experienced an objective response.
- The response rate was similar for first- and second-line treatments.
- All patients achieved disease control.
- Grade 3 treatment-related adverse events included hypertension (38%), proteinuria (17%), and platelet count decrease (7%).
- There were no grade 4 treatment-related adverse events, serious treatment-related adverse events, or treatment-related deaths.
- Open-label, single institution.